CD Biosynsis offers accelerated CHO (Chinese Hamster Ovary) Cells Strain Development and Screening Services, utilizing advanced genetic tools and high-throughput platforms to significantly speed up the optimization cycle for this critical mammalian host. CHO cells are the industry workhorse for producing complex biotherapeutics, including monoclonal antibodies (mAbs) and fusion proteins. Our services leverage high-precision genome editing (CRISPR-Cas9, Base Editing) with automated High-Throughput Screening (HTS) technologies to quickly generate, evaluate, and optimize thousands of genetic variants. We specialize in engineering CHO cell lines for enhanced specific productivity (Qp), extended culture longevity (anti-apoptosis), improved product quality (e.g., glycoprofile), and robustness against industrial stressors, providing a fast track to the commercial Master Cell Bank (MCB).
Get a QuoteStrain development in CHO cells requires the creation and testing of large libraries of highly complex genetic variants. Our integrated platform significantly accelerates the iterative optimization cycle by utilizing CRISPR-mediated stable gene integration (Knock-in into genomic safe harbors) and anti-apoptotic engineering (Knockout) to maximize the host's fitness. We couple this with automated liquid handling, miniaturized bioreactor simulations, and multi-parameter HTS assays to quickly evaluate monoclonal cell lines for critical quality attributes (CQAs) and productivity (Qp). This rapid, data-driven approach dramatically reduces the timeline for establishing a verified, high-performance CHO cell line.
CRISPR-Cas9 Editing (KI/KO)
Used for stable integration of expression cassettes into safe harbor loci (HDR) and clean multi-allelic deletion of undesirable genes (NHEJ/HDR) in CHO cells.
Base Editing (BE) / CRISPRi
For high-precision, single-nucleotide substitutions (BE) or tunable repression (CRISPRi) used to fine-tune regulatory elements and metabolic flux.
Optimized Delivery (RNP/Virus)
Preference for Ribonucleoprotein (RNP) delivery to ensure transient, high-efficiency, and low off-target editing, critical for the complex CHO genome.
Automated Single-Cell Cloning
Use of automated cell sorters (e.g., FACS, ClonePix) to isolate single, viable cells into microplates, ensuring the generation of true monoclonal cell lines.
Productivity Assays (ELISA/BLI)
Implementation of rapid, high-throughput assays (ELISA, Bio-Layer Interferometry) to quantify specific productivity (Qp) and titer directly from small culture volumes.
Miniaturized Bioreactor Systems
Use of multi-well plate systems (e.g., ambr® 15) to simulate fed-batch industrial conditions, enabling early stability and performance assessment.
Anti-Apoptosis & Longevity
Knockout of pro-apoptotic genes (e.g., Bax) or tuning of cell cycle regulators to extend the cell culture lifespan and boost final titer.
Glycoprofile Optimization
Targeted editing of native glycosylation pathways (e.g., FUT8 KO, GNAT KI) to ensure the therapeutic product exhibits the desired human-like glycan profile.
Metabolic Pathway Control
Engineering pathways to reduce toxic byproduct formation (lactate, ammonia) and enhance nutrient utilization for robust, long-term growth.
Integrated cycle for rapid, iterative strain optimization using advanced tools.
1. Rational Design & Library Generation
2. Genomic Modification & Selection
3. High-Throughput Screening & Cloning
4. Clonal Verification & MCB Delivery
Computational modeling identifies optimal genetic modifications (KO, KI, tuning) and designs the expression strategy.
Design gRNAs/primers and construct DNA libraries (e.g., promoter or UTR variants) for targeted editing.
Select the final target gene integration site (genomic safe harbor) for stable expression.
Construct expression vector or RNP/donor complex; deliver editing system into CHO cells (Build).
Execute multiplexed gene editing and select for stable integration clones (e.g., DHFR/GS amplification).
Genotype the bulk population to confirm successful editing and integration.
Analyze HTS data to correlate genotype with desired phenotype (Qp, stability) and select the lead clone (Learn).
Genomic verification (sequencing) and stability testing of the final clone over multiple passages.
Delivery of the verified CHO master cell bank (MCB) and comprehensive documentation.
Integrated DBTL Platform
Combines rational design, precision editing (CRISPR/BE/CRISPRi), and automated HTS, guaranteeing a highly accelerated and data-driven development process.
Early CQA Screening
HTS platform is optimized for early screening of Critical Quality Attributes (e.g., charge variants, aggregation) alongside titer, minimizing the selection of clones with poor quality.
Stable Monoclonal Lines
Focus on CRISPR/HDR integration into defined genomic safe harbors and automated single-cell cloning ensures genetic stability and true clonality for regulatory acceptance.
Enhanced Anti-Apoptosis
Targeted anti-apoptotic engineering (KO/CRISPRi) extends cell viability and productivity in the bioreactor, translating directly into higher final product yields.
1. What is the role of HTS in CHO cell line development?
HTS is crucial for rapidly screening thousands of single-cell clones after transfection/editing. It identifies clones with the highest specific productivity (Qp) and desired quality attributes (CQAs) in miniaturized culture systems, accelerating the selection process.
2. How do you ensure the final cell line is truly monoclonal?
We use automated single-cell cloning technologies (e.g., FACS or specialized clonality platforms) to ensure that only a single cell is deposited into each microplate well, guaranteeing clonality for regulatory documentation.
3. How does Base Editing help optimize the CHO cell line?
Base Editing provides single-nucleotide precision to fine-tune regulatory sequences (promoters, UTRs) or introduce subtle beneficial mutations into metabolic enzymes (e.g., LDHA), safely enhancing cell fitness or reducing byproducts.
4. Why is anti-apoptosis engineering necessary?
In a fed-batch bioreactor, CHO cells eventually die due to nutrient depletion and stress. Anti-apoptosis engineering (KO/CRISPRi of pro-apoptotic genes) extends the viable phase, leading to higher cumulative and final product titer.
5. How is product quality (CQAs) screened early in the process?
We use CQA-specific HTS assays, such as high-throughput Western Blot or rapid charge variant analysis (e.g., IEF), to evaluate the glycosylation profile, aggregation levels, and charge variants of the product produced by early-stage clones.
6. What is the advantage of integrating the gene into a "safe harbor"?
Integration into a genomic safe harbor (via CRISPR/HDR) ensures that the therapeutic gene is placed in a consistently transcribed region, guaranteeing stable, high-level expression and preventing gene silencing over long culture periods.
7. What is included in the Master Cell Bank (MCB) delivery?
The MCB consists of a large, cryopreserved batch of the final verified clonal cell line, accompanied by a comprehensive report, stability data, and genomic verification documentation, ready for regulatory filing.
8. What input materials are needed to start a strain development project?
We require the specific CHO host cell line (e.g., CHO-K1, CHO-DG44) and the full sequence of the gene of interest (GOI), including the desired promoter and any critical quality targets (CQAs).
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.